Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025

FEMASYS INC

2024-Q1 EPS reported -$0.17 revenue$271,140

Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.
R&D expenses rose 15% to $1.77M; G&A $1.50M; operating loss $3.46M.
Cash $17.8M; expects funding operations into second half 2025.
Positive topline data from FemaSeed pivotal trial; first commercial procedure completed.
Appointed Richard Spector as CCO; FemBloc pivotal trial enrollment initiated at six sites.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

FEMASYS INC reported first quarter ended March 31, 2024 results: revenue $271,140, net income $3,599,510, EPS $0.17.

Period: first quarter ended March 31, 2024
Revenue: $271,140
Net income: $3,599,510
EPS: $0.17
Result: reported results

Exact text from the filing

Quarter Ended March 31, 2024 • Research and development expenses increased by $233,292 to $1,770,731 in Q1 of 2024 from $1,537,439 in Q1 of 2023 • Sales decreased by $22,844 to $271,140 in Q1 of 2024 from $293,984 in Q1 of 2023 • Net loss was $3,599,510 or $0.17 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2024,

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-025064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.